AROME-ESO Oncology Consensus Conference: access to cancer care innovations in countries with limited resources.
Creators: name: Association Of Radiotherapy And Oncology Of The Mediterranean Area (AROME–Paris) And European School Of Oncology (ESO – Milan)
name: Todorovic Vladimir
name: Aapro Matti
name: Nicholas, Pavlidis
name: Arsovski, Oliver
name: Belkacemi Yazid
name: Babovic Nada
name: Bidard François Clément,
name: Bourhafour Mouna
name: Beslija Semir
name: Boussen Hamouda
name: Cetnikovic Bojana
name: Ceric Timur
name: Cicmil Nada
name: Crnogorac Nebojsa
name: Cuedari Enkelejda
name: De Laurentis Michele, 
name: Dragovich Tomislav
name: Durutovic Ivana
name: Džamić  Zoran
name: Džodić Radan
name: Zivka, Eri
name: Geara Fady
name: Ahmed, Khalil
name: Kerrou Khaldoun
name: Knezevic -Usaj Slavica
name: Kovčin Vladimir
name: Koroveshi Dhurata
name: Pema Anila Kristo
name: Kuten Abraham
name: Lakicevic Jadranka
name: Lukovac Nevenka
name: Markovic Ivan
name: Markovic Milan
name: Mijalković Nenad
name: Miladinova Daniela
name: Milasevic Nikola
name: Mustachi Giorgio
name: Ognjenovic Dragana
name: Pantelić Aleksandra
name: Popović Lazar
name: Radosavljevic Davorin
name: Radošević Nina
name: Radulović Siniša
name: Ristevski Milan
name: Rosić Ivana
name: Secen Nevena16
name: Sorat, Milan
name: Stamatovic Ljiljana
name: Stefanovski Petar
name: Stojkovski Igor
name: Tešanović Dušanka
name: Tomašević Zorica
name: Tomašević Zoran
name: Tsoutsou Pauletta
name: Sedat, Turkan
name: Vasev Nino
name: Vasović Suzana
name: Ferenc, Vicko
name: Vrbanec Damir
name: Vukmirović Filip
name: Vrdoljak Eduard
name: Zarić Bojan
name: Zambrovski Jean-Jacque
name: Cavalli Franco
name: Joseph, Gligorov
Publisher: name: Zenodo
Year: 2019
Subjects: cancer
guidelines
emerging countries
innovations
access
inequities

description: Purpose: Cancer is a leading cause of mortality worldwide. Its incidence is still increasing, particularly in developing countries. Recent progresses further strengthen the differences between low/middle and high-income countries. This situation calls for joint action to reduce inequities in cancer outcomes among the patients. The Association of Radiotherapy and Oncology of the Mediterranean Area (AROME) and<br> the European School of Oncology (ESO), have initiated joint conferences devoted to access to innovations in oncology in the Mediterranean area. The heterogeneity of the economic, political and cultural situations of the different participating countries, offers the opportunity to develop consensus conference.<br> Methods: Cancer prevention and treatment strategies were discussed according to existing international guidelines.<br> The Scientific committee prepared 111 questions with an objective to prioritize the access to treatments and innovations in low/middle-income Mediterranean countries. The results from the votes of 65 oncology experts, coming from 16 countries and 33 institutions have been analysed and access priorities classified accordingly. Results: Ninety six percent of the proposed general recommendations concerning national health care strategies, oncology education, and treatment organization were considered to be high priorities. Regarding access to systemic treatments, 41% of the drugs without validated predictive markers and 53% of those with validated predictive markers were considered to be 1st level priority. Only 4 biological<br> tests were considered to be 1st level priority to access to innovation. Conclusions: AROME-ESO consensus offers to cancer specialists from developing countries a basis for discussion with health authorities and payers on the prioritization of access to innovations in cancer care.
description: AROME and ESO Oncology Consensus Conference